Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study
Authors:
- 6 February 2021
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 24 (4) , 790-799
Abstract
Background Among patients not undergoing curative-intent therapy for esophagogastric cancer, access to care may vary. We examined the geographic distribution of care delivery and survival and their relationship with distance to cancer centres for non-curative esophagogastric cancer, hypothesising that patients living further from cancer centres have worse outcomes. Methods We conducted a population-based analysis of adults with non-curative esophagogastric cancer from 2005 to 2017 using linked administrative healthcare datasets in Ontario, Canada. Outcomes were medical oncology consultation, receipt of chemotherapy, and overall survival. Using geographic information system analysis, we mapped locations of cancer centres and outcomes across census divisions. Bivariate choropleth maps identified regional outcome discordances. Multivariable regression models assessed the relationship between distance from patient residence to the nearest cancer centre and outcomes, adjusting for demographic, clinical, and socioeconomic factors. Results Of 10,228 patients surviving a median 5.1 months (IQR: 2.0–12.0), 68.5% had medical oncology consultation and 32.2% received chemotherapy. Certain distances (reference ≤ 10 km) were associated with lower consultation [relative risk 0.79 (95% CI 0.63–0.97) for ≥ 101 km], chemotherapy receipt [relative risk 0.67 (95% CI 0.53–0.85) for ≥ 101 km], and overall survival [hazard ratio 1.07 (95% CI 1.02–1.13) for 11–50 km, hazard ratio 1.13 (95% CI 1.04–1.23) for 51–100 km]. Conclusion A third of patients did not see medical oncology and most did not receive chemotherapy. Outcomes exhibited high geographic variability. Location of residence influenced outcomes, with inferior outcomes at certain distances > 10 km from cancer centres. These findings are important for designing interventions to reduce access disparities for non-curative esophagogastric cancer care.Keywords
Funding Information
- Canadian Institutes of Health Research Partnerships for Health System Improvement (154131)
This publication has 59 references indexed in Scilit:
- Potential for patient-physician language discordance in OntarioBMC Health Services Research, 2013
- Universal health coverage and universal accessBulletin of the World Health Organization, 2013
- Disparity in Cancer Care: A Canadian PerspectiveCurrent Oncology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Centralization of Cancer Surgery: Implications for Patient Access to Optimal CareJournal of Clinical Oncology, 2009
- Demographic Differences between Cancer Survivors and those who Die Quickly of their DiseaseClinical Oncology, 2008
- Access to Cancer Services for Rural Colorectal Cancer PatientsThe Journal of Rural Health, 2008
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Effects of Socioeconomic Status on Access to Invasive Cardiac Procedures and on Mortality after Acute Myocardial InfarctionNew England Journal of Medicine, 1999
- Trunk muscle forces during desk workErgonomics, 1986